Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“Lung cancer care is evolving, bringing new hope to patients.
Over the last decade, our unwavering commitment has fueled the development of powerful targeted therapies, raising the bar for treatment and positively impacting thousands of patients across all stages of lung cancer.
Michael Gibney‘s recent PharmaVoice article, spotlights AstraZeneca’s long-term strategy in treating EGFR-mutated non-small cell lung cancer and how bold science, long-term vision, and relentless collaboration is driving real impact for patients.
Read more about our journey.”
More posts featuring Mohit Manrao.